MedTrace Logo

Latent Tuberculosis in Type 2 Diabetes

NCT06874725 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 552

Last updated 2025-03-13

No results posted yet for this study

Summary

The patients with poorly controlled DM underwent LTBI screening by using QuantiFERON (QFT). QFT-positivity predictors were evaluated. The patients with LTBI received tuberculosis preventive therapy, 9 months of daily isoniazid (9H) or 3 months of weekly rifapentine plus isoniazid (3HP), administered by pulmonologists. The completion rates and inflammatory markers were also investigated.

Conditions

  • Latent Tuberculosis Infection

Interventions

DRUG

Rifapentine and Isoniazid for 3 months

tuberculosis preventive therapy (TPT) with 3 months of weekly rifapentine plus isoniazid (3HP)

DRUG

Isoniazid (INH) daily for 9 months

tuberculosis preventive therapy (TPT) with 9 months of daily isoniazid (9H)

Sponsors & Collaborators

  • Taichung Veterans General Hospital

    lead OTHER

Principal Investigators

  • I-Te Lee · Taichung Veterans General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-18
Primary Completion
2024-04-30
Completion
2025-04-18

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06874725 on ClinicalTrials.gov